Erdafitinib versus enfortumab vedotin in previously treated urothelial carcinoma

Michael Devitt, MD, a hematologist/oncologist and assistant professor at the University of Virginia Medical Center, discusses considerations when choosing between erdafitinib and enfortumab vedotin in previously treated urothelial carcinoma.

Erdafitinib (Balversa) is approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Enfortumab vedotin-ejfv (Padcev) is approved by the FDA for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.